Table 1: Patient demographics and baseline ocular characteristics in the PRN and 3 monthly initial dose groups.

PRN group ( )Three monthly initial dose group ( )

Age 0.46
Sex: male, female32 : 3713 : 130.75
Diabetes mellitus (%)4 (5.8%)4 (15.4%)0.21
Hypertension (%)30 (43.5%)11 (42.3%)0.92
Location of retinal vein occlusion,
ST BRVO : IT BRVO
40 : 2918 : 80.32
Pretreatment visual acuity, log MAR
(range: 0.22–1.7)

(range: 0.22–1.4)
0.61
Ischemic* BRVO: non-ischemic BRVO38 : 3116 : 100.57
OCT findings
 Pretreatment central retinal thickness, m 0.58
 Photoreceptor IS-OS status,
 Normal : disrupted (%)
21 : 48
(30.4% : 69.6%)
8 : 18
(30.8% : 69.2%)
1.0
 Photoreceptor ELM status,
 Normal : disrupted (%)
37 : 32
(53.6% : 46.4%)
14 : 12
(53.8% : 46.2%)
1.0
 Serous macular detachment (%)34 (49.3%)14 (53.8%)0.69
Funduscopic and angiographic findings
 Foveal nonperfusion (%)16 (23.2%)5 (19.2%)0.68
 Area of retinal hemorrhage, % 0.10
 Area of capillary nonperfusion, % 0.76

BRVO: branch retinal vein occlusion; ELM: external limiting membrane; IS-OS: inner segment-outer segment; IT: inferior temporal; ST: superior temporal.
value was obtained by student’s -test for continuous variables and chi-square or Fisher’s exact test for dichotomous variables.
*Nonperfused area divided by the optic disc area ≥5.
Foveal nonperfusion was defined as the extent of capillary dropout on the fovea for >1 quadrant.
The area of retinal hemorrhage or capillary nonperfusion was measured in a circle with a radius of 3600  m centred on the fovea using Image software. By dividing this area by the area of the circle with a radius of 3600  m, the percentage of the area of retinal hemorrhage or capillary nonperfusion was calculated.